Close Menu

NEW YORK – In separate lawsuits filed against Qiagen and several of its executives in the US District Court for the Southern District of New York this month, two of the company’s shareholders are alleging that Qiagen violated federal securities laws in relation to its planned acquisition by Thermo Fisher Scientific, announced in early March.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.